TMO Stock Recent News
TMO LATEST HEADLINES
Explore how Thermo Fisher's (TMO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Bill Baruch, founder and president at Blue Line Capital, joins CNBC's “Halftime Report” to explain why he's buying Thermo Fisher here.
CHICAGO--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, showcases its innovations in improving clinical and diagnostic laboratory efficiency and workflow optimization during the Association for Diagnostics & Laboratory Medicine Conference (ADLM), July 27-31, 2025, in Chicago, Ill. The company debuts two new solutions, LabLink360™* and Thermo Scientific™ MAS™ Max quality controls, designed to support quality control assurance and streamline workflows in clini.
WALTHAM, Mass.--(BUSINESS WIRE)--As the world leader in serving science, Thermo Fisher Scientific is proud to announce the launch of two new electron microscopes that will be unveiled at Microscopy & Microanalysis (M&M) in Salt Lake City, Utah, July 27-31, each significantly contributing to the democratization of research in the sciences. Scios 3 FIB-SEM offers high-powered versatility The Thermo Scientific™ Scios™ 3 is a focused ion beam (FIB) scanning electron microscope (SEM) with au.
Thermo Fisher Scientific (TMO 10.83%), a leader in life sciences tools and diagnostics, reported its second quarter 2025 results on July 23, 2025. The company outpaced expectations on both revenue and non-GAAP EPS, delivering $10.85 billion in revenue and $5.36 in non-GAAP EPS versus analyst estimates of $10.68 billion and $5.23, respectively.
Thermo Fisher Scientific (TMO) shares took off after the maker of lab equipment and other life sciences products posted better-than-expected results and boosted its guidance, citing operational improvements and lower expected impacts from new tariffs.
Shares of Thermo Fisher Scientific Inc (NYSE:TMO, ETR:TN8) jumped nearly 12% on Wednesday morning after the company reported second-quarter results that topped Wall Street estimates, fueled by strong demand across its life sciences and diagnostics segments. The company posted revenue of $10.86 billion, surpassing analysts' expectations of $10.69 billion and marking a 3% year-over-year increase.
TMO tops Q2 estimates as new product launches and solid segment growth fuel revenue gains despite margin pressure.
Thermo Fisher Scientific Inc. (NYSE:TMO ) Q2 2025 Earnings Conference Call July 23, 2025 8:30 AM ET Company Participants Marc N. Casper - Chairman, President & CEO Rafael Tejada - Vice President of Investor Relations Stephen Williamson - Senior VP & CFO Conference Call Participants Daniel Anthony Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Daniel Gregory Brennan - TD Cowen, Research Division Jack Meehan - Nephron Research LLC Michael Leonidovich Ryskin - BofA Securities, Research Division Rachel Marie Vatnsdal Olson - JPMorgan Chase & Co, Research Division Tycho W.